Aktis Oncology (NASDAQ:AKTS) Stock Price Down 10% – Should You Sell?

Aktis Oncology (NASDAQ:AKTS)’s stock price traded down 10% on Monday . The stock traded as low as $30.12 and last traded at $28.5720. Approximately 53,438 shares traded hands during trading, a decline of 84% from the average daily volume of 334,355 shares. The stock had previously closed at $31.76.

Analyst Ratings Changes

AKTS has been the subject of a number of research reports. Weiss Ratings upgraded shares of Aktis Oncology from a “sell (d)” rating to a “sell (d+)” rating in a report on Tuesday, June 23rd. Raymond James Financial began coverage on shares of Aktis Oncology in a research report on Monday, June 15th. They issued a “strong-buy” rating and a $40.00 price target for the company. William Blair started coverage on shares of Aktis Oncology in a research note on Wednesday, April 29th. They set an “outperform” rating for the company. Finally, HC Wainwright lifted their price target on shares of Aktis Oncology from $33.00 to $35.00 and gave the stock a “buy” rating in a report on Tuesday, June 2nd. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $34.00.

Aktis Oncology Stock Down 10.2%

The company has a 50-day moving average price of $21.99. The firm has a market capitalization of $1.52 billion and a PE ratio of -75.03.

Aktis Oncology (NASDAQ:AKTS) last announced its quarterly earnings data on Monday, March 30th. The technology company reported ($18.17) earnings per share (EPS) for the quarter. The firm had revenue of $1.87 million during the quarter. Equities research analysts expect that Aktis Oncology will post -1.62 earnings per share for the current year.

About Aktis Oncology

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.